

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468

Status	RECRUITING
Phase	Phase 3
Sponsor	Texas Retina Associates
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign/date a health information release (HIPAA form) before any study procedures are performed.
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to e1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid/immunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment.
- Presence of active posterior segment inflammation as determined by the Investigator.
- Vitreous haze grade e 2 based on the standardization of uveitis nomenclature (SUN) criteria.

... and 2 more (see full listing online)

Exclusion (14)

- Subjects with known hypersensitivity to any components of YUTIQ.
- Female subjects who are pregnant or breastfeeding.
- Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.
- History of anterior uveitis only (without associated uveitis that affected the posterior segment).
- Presence of a vitreous hemorrhage.

... and 9 more (see full listing online)

Locations (1 total)

Texas Retina Associates, Plano, Texas, United States